Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

April 29, 2025

The validation study recently published in the Journal of Molecular Diagnostics

CHICAGO--(BUSINESS WIRE)--Apr. 29, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the *Journal of Molecular Diagnostics*. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression.

The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinical research. Originally introduced in 2022, the xF+ panel covers 523 genes spanning ~1.8 Mb of the human genome. The validation study shows that the xF+ assay shows concordance with the Tempus xF and xT assays for MSI status and gene coverage. The assay exhibits accuracy, sensitivity, specificity, and repeatable and reproducible precision, confirmed through clinical samples, multiple replicates of reference standards, synthetic cell lines, and healthy control samples.

“When we first introduced xF+ in 2022, it was one of the largest clinically available liquid biopsy panels offered to physicians,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “We have since continued to refine the assay, and are thrilled to further demonstrate its analytical validity in a peer-reviewed study.”

To read the full study, visit tempus.com/publications.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community, and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250429855224/en/

Erin Carron
media@tempus.com

Source: Tempus AI, Inc.